Solasia Pharma KK (9SO) Price & Analysis

Compare

0 Followers

9SO Stock Chart & Stats

€0.14

<€0.01(2.88%)

At close: Jan 08 4:00 PM EST

€0.14

<€0.01(2.88%)

Day’s Range― - ―

52-Week Range€0.13 - €0.24

Previous CloseN/A

Volume0.00

Average Volume (3M)35.00

Market Cap

€45.68M

Enterprise Value€6.70B

Total Cash (Recent Filing)€1.39B

Total Debt (Recent Filing)€159.00M

Price to Earnings (P/E)―

Beta<0.01

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding269,209,000

10 Day Avg. Volume107

30 Day Avg. Volume35

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)3.93

Price to Sales (P/S)16.06

P/FCF Ratio-8.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetLow leverage and sizeable equity give the company financial flexibility to fund R&D and operations while losses persist. This reduces near-term refinancing pressure, lengthening runway and preserving strategic optionality for partnerships or selective investments over the next several quarters.

Revenue ReboundA strong revenue recovery indicates improving commercial traction or higher product uptake, which can increase operating leverage if sustained. If the company continues to grow revenues, fixed-cost absorption can materially narrow losses and support a multi-quarter path toward break-even.

Margin Base And Improving Cash BurnA relatively solid gross margin plus a noticeable reduction in free cash flow burn show the business can generate better unit economics as sales scale. Sustained margin levels and continued improvement in cash burn are structural positives for future profitability and capital efficiency.

Bears Say

Structural UnprofitabilityPersistently large operating and net losses imply the core cost base remains far above revenues. Without durable margin expansion or materially higher sales, continued losses will erode equity and constrain strategic options, making sustained profitability uncertain over several quarters.

Consistent Negative Cash FlowRepeated negative operating and free cash flow forces reliance on external financing or depletion of balance-sheet reserves. Even with improved burn in 2025, ongoing negative cash flow creates funding risk and potential dilution unless a clear path to sustained positive cash generation is established.

Small Operating ScaleA very small workforce limits commercial reach, internal R&D throughput and ability to scale operations independently. This elevates execution risk, increases reliance on partners or outsourcing, and can slow revenue diversification needed to absorb fixed costs and reach sustainable margins.

Solasia Pharma KK News

Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs

Solasia Pharma KK ( ($JP:4597) ) has provided an update. Solasia Pharma has provided an update on its...

10d ago

Solasia Pharma Narrows Losses on Higher Sales but Withholds 2026 Outlook

Solasia Pharma KK ( ($JP:4597) ) just unveiled an update. Solasia Pharma reported a 35.4% year-on-year increase in...

10d ago

Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs

Solasia Pharma KK ( ($JP:4597) ) has provided an update. Solasia Pharma has updated investors on the status...

10d ago

Solasia Pharma Narrows Losses as Sales Rise but Withholds 2026 Forecast

The latest announcement is out from Solasia Pharma KK ( ($JP:4597) ). Solasia Pharma reported a 35.4% year-on-year...

10d ago

Solasia Grants MAAB Exclusive China Rights to Sancuso in Sales Framework Overhaul

Solasia Pharma KK ( ($JP:4597) ) has provided an announcement. Solasia Pharma has signed a license agreement granting...

1M ago

Solasia Pharma Cuts FY2025 Sales Outlook on China Delays and License Changes

The latest announcement is out from Solasia Pharma KK ( ($JP:4597) ). Solasia Pharma has revised downward its...

2M ago

Solasia Pharma Expands Global Reach with Strategic Partnerships

Solasia Pharma KK ( ($JP:4597) ) just unveiled an announcement. Solasia Pharma K.K. has announced its consolidated financial...

3M ago

Solasia Pharma Reports Nine-Month Financial Results with Sales Growth Amidst Challenges

Solasia Pharma KK ( ($JP:4597) ) has provided an update. Solasia Pharma K.K. reported its consolidated financial results...

3M ago

Solasia Pharma Reports Q2 Financials and Pipeline Progress

Solasia Pharma KK ( ($JP:4597) ) has issued an update. Solasia Pharma K.K. announced its consolidated financial results...

6M ago

Solasia Pharma Reports First Half 2025 Financial Results Amid Ongoing Challenges

Solasia Pharma KK ( ($JP:4597) ) has issued an announcement. Solasia Pharma K.K. reported its consolidated financial results...

6M ago

9SO FAQ

What was Solasia Pharma KK’s price range in the past 12 months?

Solasia Pharma KK lowest stock price was €0.13 and its highest was €0.24 in the past 12 months.

What is Solasia Pharma KK’s market cap?

Solasia Pharma KK’s market cap is €45.68M.

When is Solasia Pharma KK’s upcoming earnings report date?

Solasia Pharma KK’s upcoming earnings report date is May 20, 2026 which is in 86 days.

How were Solasia Pharma KK’s earnings last quarter?

Solasia Pharma KK released its earnings results on Feb 13, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.

Is Solasia Pharma KK overvalued?

According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Solasia Pharma KK pay dividends?

Solasia Pharma KK does not currently pay dividends.

What is Solasia Pharma KK’s EPS estimate?

Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Solasia Pharma KK have?

Solasia Pharma KK has 269,209,000 shares outstanding.

What happened to Solasia Pharma KK’s price movement after its last earnings report?

Solasia Pharma KK reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.974%.

Which hedge fund is a major shareholder of Solasia Pharma KK?

Currently, no hedge funds are holding shares in DE:9SO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Solasia Pharma KK

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.